Sensorion Advances SENS-601 for GJB2-Related Hearing Loss

Sensorion, a clinical-stage biotechnology firm, announces significant progress for SENS-601, a gene therapy targeting GJB2-related hearing loss. Clinical trial applications are submitted in Canada and France, with a Fast Track status granted by France's ANSM. The U.S. and Australia are set for applications by the end of 2026.

SENS-601 stems from collaboration with the Institut Pasteur and focuses on GJB2, a common cause of genetic deafness. Following strategic evaluation, Sensorion discontinues SENS-501 to focus on SENS-601, extending its cash runway to the end of 2027.

CEO Fred Chereau emphasizes the strategic shift towards SENS-601, leveraging robust foundational research. The initiative aims to address a significant patient population lacking approved therapies.